

BREAKING THROUGH

Overcoming challenges in the treatment of patients with triple-negative and HR+/HER2– metastatic breast cancer

Gilead Symposium

Friday 12 May 2023, 12:30–13:30 (CEST)
Munich Hall, Hub27-Messe Berlin, Germany

Please join us for an interactive session around the optimal management and everyday challenges that clinicians face in the treatment of patients with triple-negative and HR+/HER2– metastatic breast cancer.



12:30–12:40



Welcome and introduction

Treatment landscape and emerging needs in metastatic breast cancer: Where are we today?

Prof. Dr Wolfgang Janni (Chair)

Medical Director, Women's Clinic Director, Department of Obstetrics and Gynecology, University Hospital Ulm, Ulm, Germany

12:40–13:10



Optimal management in mTNBC: What have we learned from clinical practice?

A patient case discussion and clinical data presentation accompanied by scientific exchange with the audience

Dr Mafalda Oliveira

Medical Oncologist, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Vall d'Hebron Barcelona Hospital Campus, SOLTI Breast Cancer Research Group, Barcelona, Spain

13:10–13:30



A new era of treatment for HR+/HER2– mBC: What do the clinical data tell us?

A patient case discussion and clinical data presentation accompanied by scientific exchange with the audience

Dr Komal Jhaveri

Associate Attending Physician, Breast Medicine Service and Early Drug Development Service, Section Head of the Endocrine Therapy Research Program, and Clinical Director of the Early Drug Development Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, and Assistant Professor of Medicine, Weill Cornell Medical College, New York, USA

13:30

Closing remarks

Prof. Dr Wolfgang Janni

HER2, human epidermal growth factor receptor 2; HR, hormone-receptor; mBC, metastatic breast cancer; mTNBC, metastatic triple-negative breast cancer.